Global Cardiovascular Drugs Markets, 2014-2018 & 2019-2022 Featuring Merck & Co, Sanofi, Pfizer, Bristol-Myers Squibb Co, Novartis -

DUBLIN--()--The "Cardiovascular Drugs Global Market Report 2019" report has been added to's offering.

Global Cardiovascular Drugs Market Report 2019 provides the strategists, marketers and senior management with the critical information they need to assess the global cardiovascular drugs market.

Where is the largest and fastest growing market for the cardiovascular drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Cardiovascular Drugs market global report answers all these questions and many more.

The cardiovascular drugs market consists of sales of cardiovascular drugs and related services by entities (organizations, sole traders and partnerships) that produce cardiovascular drugs to treat cardiovascular diseases. This industry includes establishments that produce anti-hypertensive drugs to prevent heart failure by controlling blood pressure and hypolipidemic drugs that reduce lipid and lipoprotein levels in the blood. It also consists of establishments which produce antithrombotic drugs to treat arterial and venous thrombosis.

Asia Pacific was the largest region in the global cardiovascular drugs market, accounting for 39% of the market in 2018. North America was the second largest region accounting for 26% of the global cardiovascular drugs market. Africa was the smallest region in the global cardiovascular drugs market.

NOACs are gaining wider acceptance and are replacing traditionally used anti-coagulants such as Warfarin and Heparin. Anti-coagulants have long been used in prevention of thrombus formation in patients suffering with cardiovascular diseases. Use of NOACs makes it easier for patients to continue therapy post discharge as opposed to injections of Heparin and Warfarin which need medical assistance for administration xxviii. Some of the NOACs include Pradaxa (dabigatran etexilate) from Boehringer Ingelheim, Xarelto (rivaroxaban) from Janssen, and Eliquis (apixaban) from Bristol-Myers Squibb.

Key Topics Covered:

1. Executive Summary

2. Report Structure

3. Cardiovascular Drugs Market Characteristics

3.1. Market Definition

3.2. Key Segmentations

4. Cardiovascular Drugs Market Product Analysis

4.1. Leading Products/ Services

4.2. Key Features and Differentiators

4.3. Development Products

5. Cardiovascular Drugs Market Supply Chain

5.1. Supply Chain

5.2. Distribution

5.3. End Customers

6. Cardiovascular Drugs Market Customer Information

6.1. Customer Preferences

6.2. End Use Market Size and Growth

7. Cardiovascular Drugs Market Trends And Strategies

8. Cardiovascular Drugs Market Size And Growth

8.1. Market Size

8.2. Historic Market Growth, Value ($ Billion)

8.2.1. Drivers Of The Market

8.2.2. Restraints On The Market

8.3. Forecast Market Growth, Value ($ Billion)

8.3.1. Drivers Of The Market

8.3.2. Restraints On The Market

9. Cardiovascular Drugs Market Regional Analysis

9.1. Global Cardiovascular Drugs Market, 2018, By Region, Value ($ Billion)

9.2. Global Cardiovascular Drugs Market, 2014 - 2022, Historic And Forecast, By Region

9.3. Global Cardiovascular Drugs Market, Growth And Market Share Comparison, By Region

10. Cardiovascular Drugs Market Segmentation

10.1. Global Cardiovascular Drugs Market, Segmentation By Type, 2014 - 2022, Value ($ Billion)

10.1.1. Anti-Hypertensive Drugs

10.1.2. Hypolipidemics

10.1.3. Anti Thrombotics

10.1.4. Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrhythmic And Anti-Anginal Drugs)

11. Cardiovascular Drugs Market Metrics

11.1. Cardiovascular Drugs Market Size, Percentage Of GDP, 2014 - 2022, Global

11.2. Per Capita Average Cardiovascular Drugs Market Expenditure, 2014 - 2022, Global

Companies Mentioned

  • Merck & Co
  • Sanofi S.A
  • Pfizer Inc
  • Bristol-Myers Squibb Company
  • Novartis AG

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiovascular Drugs

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiovascular Drugs